BPC-157 10mg (3ml)

Description

BPC-157 Research Overview

---

Executive Summary

BPC-157 (Body Protection Compound-157) stands as one of the most extensively studied synthetic peptides in regenerative medicine research. This 15-amino acid peptide, derived from a naturally occurring protein in human gastric juice, has been the subject of over 100 peer-reviewed studies spanning more than three decades. Originating from research at the University of Zagreb under Dr. Predrag Sikiric, BPC-157 has been studied for tissue-repair activity across multiple tissue types in preclinical models.

The peptide's unique mechanism of action involves modulation of the nitric oxide system, upregulation of critical growth factors (VEGF, EGF, FGF), activation of the FAK-paxillin pathway, and interaction with GABAergic neurotransmission. These interconnected pathways have been proposed to explain the broad range of tissue responses reported in preclinical models.

While human clinical trials remain limited, the extensive body of animal research suggests potential applications in gastrointestinal healing, tendon and ligament repair, muscle recovery, neuroprotection, and cardiovascular health. This comprehensive guide examines the scientific evidence, mechanisms, and practical considerations surrounding this fascinating research compound.

---

Table of Contents

1. Introduction and Discovery
2. Molecular Structure and Origin
3. Interactive Molecular Structure
4. Detailed Mechanism of Action
5. Scientific Research Review
6. Research Areas by Category with Evidence Ratings
7. Regulatory Status
8. Side Effects and Safety Profile
9. Drug Interactions
10. Comparison with TB-500
11. Conclusion
12. References
13. Disclaimer

---

Introduction and Discovery

The Zagreb Discovery

The story of BPC-157 begins in the laboratories of the University of Zagreb School of Medicine in Croatia during the early 1990s. Dr. Predrag Sikiric, a professor of pharmacology, led a research team investigating the protective properties of proteins found in human gastric juice. Their work centered on a fundamental question: how does the stomach protect itself from its own acidic environment and rapidly heal when damaged?

Through systematic analysis of gastric proteins, Dr. Sikiric's team isolated a specific sequence from a larger protein complex they termed "Body Protection Compound" (BPC). After extensive testing of various fragments, they identified a 15-amino acid sequence that exhibited the most potent protective activity in their experimental models. This sequence became known as BPC-157, with the "157" representing the specific fragment identified through their research methodology [1].

Dr. Sikiric's Research Legacy

Dr. Sikiric has dedicated over 30 years to studying BPC-157, publishing more than 100 peer-reviewed papers on the compound. His research program has systematically examined BPC-157's effects across virtually every organ system, establishing a comprehensive scientific foundation that few other peptides can claim.

The Zagreb research group's work is notable for its methodological consistency and the breadth of applications studied. From initial gastrointestinal protection studies, the research expanded to include wound healing, musculoskeletal repair, neurological effects, cardiovascular applications, and cytoprotection against various toxins [2].

While the concentration of research within a single group has drawn some scientific criticism regarding independent verification, it has also produced an unusually coherent and detailed body of knowledge about a single compound. In recent years, independent research groups have begun to replicate some of these findings, adding credibility to the Zagreb team's extensive work.

---

Molecular Structure and Origin

The 15-Amino Acid Sequence

BPC-157's full chemical name is pentadecapeptide BPC 157, reflecting its 15-amino acid structure. The sequence is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

Or in single-letter amino acid code: GEPPPGKPADDAGLV

This specific arrangement was selected from the larger gastric BPC protein based on its superior stability and biological activity. The molecular weight is approximately 1,419 Daltons, making it a relatively small peptide that can potentially traverse biological membranes more easily than larger proteins [3].

Gastric Origin and Natural Function

The parent protein from which BPC-157 is derived exists naturally in human gastric juice at low concentrations. In its natural context, this protein appears to play a role in the stomach's remarkable ability to:

• Maintain mucosal integrity despite constant acid exposure
• Rapidly repair minor daily damage to the stomach lining
• Protect against ulcer formation
• Coordinate healing responses after injury

The synthetic BPC-157 peptide is more stable than the natural compound, allowing for consistent production and research applications. Unlike naturally occurring proteins that may degrade rapidly, BPC-157 maintains its structural integrity across various pH conditions, including the acidic environment of the stomach. This stability has been noted as a subject of ongoing preclinical investigation [4].

Synthetic Production

BPC-157 is produced through solid-phase peptide synthesis (SPPS), a standard laboratory technique for creating peptide sequences. The synthetic version is identical in structure to the corresponding fragment of the natural gastric protein, but its isolated form allows for:

• Precise quantification in research applications
• Standardized purity levels (typically 98%+)
• Consistent batch-to-batch reproducibility
• Extended shelf stability when properly stored

---

Interactive Molecular Structure

The following interactive 3D visualization renders the BPC-157 peptide backbone. The structure highlights the distinctive triple-proline motif (Pro-Pro-Pro) at positions 3-5 that contributes to the peptide's remarkable stability.

Legend: The interactive visualization above depicts the 15-residue peptide backbone of BPC-157. The highlighted region indicates the distinctive triple-proline motif (P3-P4-P5) that confers exceptional structural rigidity and acid stability. Each node represents an amino acid residue color-coded by chemical property. Drag to rotate the structure; scroll to zoom.

---

Detailed Mechanism of Action

The broad range of effects reported for BPC-157 in preclinical models appears to stem from its ability to modulate multiple interconnected biological pathways simultaneously. Rather than acting through a single receptor or mechanism, the peptide influences several systems that collectively promote tissue repair and protection.

Nitric Oxide System Modulation

One of BPC-157's most important mechanisms involves the nitric oxide (NO) system. Nitric oxide is a critical signaling molecule that regulates blood flow, inflammation, immune function, and cellular communication throughout the body.

Research has demonstrated that BPC-157 exhibits a unique "modulatory" effect on NO pathways [5]:

When NO is depleted: BPC-157 appears to upregulate nitric oxide synthase (NOS) activity and increase NO production, helping restore normal signaling.

When NO is excessive: The peptide helps normalize levels, preventing the tissue damage that can result from NO overproduction during severe inflammation.

This bidirectional regulation, rather than simple enhancement or inhibition, may explain BPC-157's apparent ability to promote healing in diverse pathological conditions. The NO system modulation also contributes to:

• Improved blood flow to injured tissues
• Reduced oxidative stress
• Enhanced cellular metabolism during repair
• Better coordination of inflammatory responses

Growth Factor Upregulation

BPC-157 has been shown to increase the expression and activity of several critical growth factors essential for tissue repair:

VEGF (Vascular Endothelial Growth Factor)

VEGF is the master regulator of angiogenesis (new blood vessel formation). Studies demonstrate that BPC-157 significantly upregulates VEGF expression, promoting the formation of new capillaries to supply healing tissues with oxygen and nutrients [6]. This effect is particularly important for:

• Wound healing
• Tendon and ligament repair (notoriously poor blood supply)
• Cardiac tissue recovery
• Gastrointestinal mucosal regeneration

EGF (Epidermal Growth Factor)

EGF promotes cell proliferation and differentiation, particularly in epithelial tissues. BPC-157's enhancement of EGF signaling contributes to:

• Accelerated skin wound closure
• Gastrointestinal mucosa regeneration
• Enhanced cellular migration to injury sites

FGF (Fibroblast Growth Factor)

FGF family members play crucial roles in wound healing, tissue development, and angiogenesis. BPC-157 upregulation of FGF contributes to:

• Fibroblast activation and collagen production
• Tissue remodeling during healing
• Blood vessel maturation

FAK-Paxillin Pathway Activation

The FAK (Focal Adhesion Kinase)-paxillin pathway is crucial for cell migration, adhesion, and survival. When tissues need to heal, cells must:

1. Detach from their current location
2. Migrate to the injury site
3. Attach properly to form new tissue
4. Organize into functional structures

Research by Chang et al. demonstrated that BPC-157 significantly activates the FAK-paxillin pathway in tendon cells (tenocytes) [7]. This activation:

• Promotes directed cell migration toward injury sites
• Enhances cellular outgrowth from damaged tissue edges
• Improves cell survival during the stressful healing process
• Facilitates proper tissue organization

This mechanism is particularly relevant for tendon and ligament healing, where cellular organization and proper fiber alignment are critical for functional recovery.

GABAergic System Interaction

BPC-157 demonstrates significant interactions with the GABAergic neurotransmitter system, which is relevant to both its neurological effects and its gastrointestinal effects observed in preclinical models (given the gut-brain axis connection).

Studies have shown that BPC-157 [8]:

• Modulates GABA receptor function
• Influences dopaminergic system activity
• Affects serotonergic pathways
• May help normalize neurotransmitter imbalances caused by various toxins

These effects contribute to BPC-157's observed:

• Anxiolytic (anti-anxiety) properties in animal models
• Protection against dopaminergic neurotoxins
• Potential applications in alcohol withdrawal and drug-induced neurological damage
• Gut motility regulation

Angiogenesis Promotion

Beyond VEGF upregulation, BPC-157 promotes angiogenesis through multiple coordinated mechanisms [9]:

• Direct stimulation of endothelial cell proliferation
• Enhanced endothelial cell migration
• Improved capillary tube formation
• Blood vessel maturation and stabilization
• Collateral vessel development around blocked arteries

This robust angiogenic effect helps explain why BPC-157 appears effective for tissues with naturally poor blood supply (tendons, ligaments, cartilage) and why it may support recovery from ischemic injuries.

---

Scientific Research Review

Gastrointestinal Studies

The gastrointestinal system represents the most extensively studied application for BPC-157, reflecting its gastric protein origins.

Gastric and Duodenal Ulcer Healing

Multiple studies have demonstrated BPC-157's remarkable ability to accelerate ulcer healing in animal models. Sikiric et al. showed that BPC-157 significantly accelerated the healing of gastric ulcers induced by:

• Cysteamine
• Aspirin and NSAIDs
• Alcohol
• Chronic restraint stress
• Surgical resection

The peptide not only accelerated healing rates but also improved the quality of healed tissue, reducing scarring and fibrosis [10].

NSAID-Induced Damage Protection

Among the most studied preclinical findings is BPC-157's protective effect against NSAID-induced gastrointestinal damage in animal models. Studies have shown [11]:

• Reduced gastric lesion formation in NSAID-exposure animal models
• Healing of existing NSAID-induced damage
• Protection of both upper and lower GI tract
• Preservation of intestinal permeability

This is particularly significant given that millions of people take NSAIDs regularly, often experiencing GI side effects.

Inflammatory Bowel Disease Models

Research using animal models of IBD (both Crohn's-like and ulcerative colitis-like conditions) has shown BPC-157 [12]:

• Reduces intestinal inflammation
• Accelerates mucosal healing
• Preserves intestinal barrier function
• Decreases inflammatory cytokine production
• Prevents fistula formation in some models

Intestinal Anastomosis Healing

Surgical studies demonstrated that BPC-157 significantly improves the healing of intestinal anastomoses (surgical connections), potentially reducing complications like leakage and stricture formation [13].

Tendon and Ligament Healing Research

Achilles Tendon Studies

The landmark study by Staresinic et al. examined BPC-157's effects on transected rat Achilles tendons [14]. Results showed:

• Significantly faster healing compared to controls
• Improved biomechanical properties of healed tendons
• Better collagen fiber organization
• Enhanced tensile strength

Follow-up studies confirmed these findings and demonstrated that BPC-157 stimulated tendon cell (tenocyte) proliferation and migration in vitro.

Medial Collateral Ligament Healing

Cerovecki et al. studied BPC-157 in an MCL injury model, demonstrating [15]:

• Accelerated ligament healing
• Improved tissue organization
• Better functional outcomes
• Enhanced collagen formation

Rotator Cuff Models

Research on rotator cuff injury models has reported similar findings, with BPC-157 associated with improved healing rates and tissue quality in these animal models.

Muscle Injury Studies

Crush Injuries

Studies on muscle crush injuries demonstrated that BPC-157 significantly accelerated recovery of muscle function and reduced the formation of fibrotic scar tissue [16].

Corticosteroid-Impaired Healing

Particularly interesting research showed that BPC-157 could overcome the healing impairment caused by systemic corticosteroid administration, maintaining near-normal healing rates even in steroid-treated animals [17].

Muscle-Tendon Junction

Research on injuries at the muscle-tendon junction (a common injury site in athletes) showed BPC-157 promoted coordinated healing of both tissue types, maintaining the integrity of this critical interface.

Neuroprotective Research

Dopaminergic System Protection

Multiple studies have demonstrated BPC-157's ability to protect dopaminergic neurons from various toxins, including [18]:

• MPTP (a toxin used to model Parkinson's disease)
• Amphetamine-induced neurotoxicity
• Haloperidol-induced catalepsy

Peripheral Nerve Healing

Research by Gjurasin et al. showed that BPC-157 significantly improved recovery following sciatic nerve injuries, with better functional outcomes and nerve regeneration compared to controls [19].

Traumatic Brain Injury

Preliminary studies in traumatic brain injury models report reduced inflammation and improved neurological outcomes in animals.

Alcohol Withdrawal and Toxicity

In animal models, BPC-157 has been studied for protective effects against alcohol-induced brain damage and in alcohol withdrawal models, where reduced anxiety-like behavior and prevention of seizures were reported [20].

Cardiovascular Studies

Cardiac Protection

Research has demonstrated BPC-157's potential cardioprotective effects [21]:

• Protection against arrhythmias induced by various drugs
• Improved cardiac function after ischemic injury
• Enhanced coronary blood flow
• Reduced infarct size in heart attack models

Blood Vessel Effects

Studies on blood vessel healing show BPC-157 promotes:

• Arterial healing after injury
• Venous healing and reduced thrombosis
• Collateral vessel development
• Endothelial function improvement

---

Research Areas by Category with Evidence Ratings

Gastrointestinal Research – Strong Preclinical Evidence

Evidence Rating: Strong (Multiple animal studies, consistent results)

The gastrointestinal applications of BPC-157 have the most robust research support:

• Ulcer healing (gastric and duodenal)
• NSAID-induced damage protection and reversal
• Inflammatory bowel conditions
• Intestinal permeability ("leaky gut")
• Esophageal damage healing
• Liver protection

The consistency of results across multiple studies and various injury models provides strong preclinical evidence. The mechanism aligns with BPC-157's gastric origins and makes biological sense.

Tendon and Ligament Repair – Moderate to Strong Evidence

Evidence Rating: Moderate-Strong (Several animal studies, some independent replication)

Research support for musculoskeletal healing is substantial:

• Achilles tendon injuries
• Ligament damage (MCL, ACL)
• Rotator cuff healing
• General tendinopathy
• Surgical repair enhancement

The FAK-paxillin mechanism and VEGF upregulation provide clear biological rationale for these effects. Independent replication of some findings strengthens the evidence base.

Muscle Recovery – Moderate Evidence

Evidence Rating: Moderate (Animal studies with consistent results)

Muscle healing research shows promising results:

• Crush injury recovery
• Strain healing
• Post-surgical muscle repair
• Overcoming steroid-induced healing impairment

While fewer studies exist compared to GI and tendon research, results are consistent and mechanisms are well-explained.

Neuroprotection – Emerging Evidence

Evidence Rating: Emerging (Interesting animal data, limited scope)

Neurological applications show promise but require more research:

• Dopaminergic system protection
• Peripheral nerve regeneration
• Traumatic brain injury
• Alcohol-related neurological damage

The GABAergic system interactions and NO modulation provide mechanistic support, but this area needs more study.

Cardiovascular – Emerging Evidence

Evidence Rating: Emerging (Preliminary animal data)

Cardiovascular applications are less studied but intriguing:

• Cardiac protection
• Arrhythmia prevention
• Blood vessel healing
• Collateral vessel formation

---

Regulatory Status

FDA Classification

BPC-157 is not approved by the FDA for any medical use in humans. It is classified as a research chemical, meaning:

• It cannot be legally marketed as a drug or supplement
• It is not recognized as "Generally Recognized as Safe" (GRAS)
• No New Drug Application (NDA) has been submitted
• It has not undergone the formal FDA approval process

Research Chemical Status

BPC-157 is available for purchase as a "research chemical" in most jurisdictions, with important caveats:

• Sold for "research purposes only"
• Not for human consumption (legally)
• No quality standards enforced by regulatory agencies
• Purity and identity depend entirely on supplier integrity

International Regulations

Regulatory status varies by country:

• United States: Research chemical, not approved for human use
• European Union: Not approved, status varies by member state
• Canada: Not approved for human use, research chemical
• Australia: Not approved, TGA Category 4 substance
• United Kingdom: Not approved for human use

Sports and Competition

BPC-157 is not specifically listed on the World Anti-Doping Agency (WADA) prohibited list, unlike TB-500. However:

• It may fall under categories for prohibited peptide hormones
• Athletes should exercise extreme caution
• Testing methodologies continue to evolve
• Some sports organizations have their own specific policies

---

Side Effects and Safety Profile

Animal Study Safety Data

The extensive animal research on BPC-157 has shown a remarkably favorable safety profile [22]:

• No observed LD50 (lethal dose) has been established, as studies have not found doses causing toxicity
• No organ toxicity observed at the highest doses tested in animal studies
• No carcinogenic effects demonstrated
• No mutagenic effects in testing
• No reproductive toxicity observed

This exceptional safety profile in animal studies is frequently cited, though translation to humans cannot be assumed.

Theoretical Concerns

Growth Factor Effects:

BPC-157's upregulation of growth factors raises theoretical concerns for:

• Cancer promotion in those with existing malignancies
• Acceleration of undiagnosed tumors
• Effects on benign growths (polyps, fibroids)

No evidence directly supports these concerns, but caution is warranted given the mechanisms involved.

Immune Modulation:

The peptide's effects on inflammatory pathways suggest caution for:

• Active autoimmune conditions
• Immunocompromised individuals
• Those taking immunomodulatory medications

---

Drug Interactions

Theoretical Interactions

Given BPC-157's mechanisms, theoretical interactions exist with:

Medications Affecting NO System:

• Nitrates (nitroglycerin, isosorbide)
• PDE5 inhibitors (sildenafil, tadalafil)
• Some blood pressure medications
• Reasoning: Combined NO system effects

Anticoagulants and Antiplatelets:

• Warfarin
• Aspirin
• Clopidogrel
• Direct oral anticoagulants
• Reasoning: Angiogenic effects may affect bleeding

Growth Hormone and Related:

• HGH
• IGF-1
• Other growth-promoting compounds
• Reasoning: Additive growth factor effects

Immunomodulators:

• Corticosteroids
• TNF-alpha inhibitors
• Other immunosuppressants
• Reasoning: Overlapping immune effects

NSAIDs – A Special Case

Interestingly, while drug interactions are generally concerning, research suggests BPC-157 may protect against NSAID damage. However, this is an off-label, unvalidated approach.

---

Comparison with TB-500

TB-500 (Thymosin Beta-4 fragment) and BPC-157 are frequently discussed together as tissue-repair research peptides. Understanding their differences helps clarify their potential applications.

Mechanisms Compared

Aspect	BPC-157	TB-500
Origin	Gastric protein fragment	Thymosin Beta-4 fragment
Primary Mechanism	NO modulation, growth factors	Actin regulation, cell migration
Key Pathway	FAK-paxillin activation	G-actin sequestration
Growth Factors	VEGF, EGF, FGF upregulation	Limited direct GF effects
Angiogenesis	Strong promotion	Moderate promotion
Neurological	GABAergic interaction	Limited CNS effects
GI Effects	Strong (origin related)	Minimal

Applications Compared

Application	BPC-157	TB-500
Tendon Healing	Strong evidence	Strong evidence
Ligament Repair	Strong evidence	Moderate evidence
Muscle Recovery	Moderate evidence	Moderate evidence
Gastrointestinal Protection	Strong evidence	Minimal/None
Cardiac	Emerging evidence	Strong evidence
Skin Wounds	Moderate evidence	Strong evidence
Hair Growth	Not studied	Limited data

Regulatory Compared

Factor	BPC-157	TB-500
WADA Status	Not explicitly listed	Prohibited
Research Stage	Extensive animal	Moderate animal, some human
FDA Status	Not approved	Not approved

---

Conclusion

BPC-157 represents one of the most intriguing and extensively studied peptides in regenerative medicine research. From its discovery in Zagreb as a fragment of gastric protective protein to over 100 published studies examining its diverse applications, the scientific foundation for BPC-157 is more substantial than most other research peptides.

Key Takeaways

The Science:

• BPC-157 works through multiple interconnected mechanisms including NO modulation, growth factor upregulation, FAK-paxillin pathway activation, and GABAergic system interaction
• The strongest preclinical evidence relates to gastrointestinal protection models, followed by tendon and ligament repair models
• Animal studies report a favorable safety profile and accelerated healing in injury models
• The lack of human clinical trials remains the most significant limitation

Practical Considerations:

• Quality and purity vary significantly between suppliers

Important Limitations:

• Not approved for human use by any regulatory agency
• Most research originates from a single research group
• Long-term effects in humans unknown
• Individual results may vary significantly from research findings

The Path Forward

For researchers interested in BPC-157, approaching this compound with informed caution is essential. Understanding the current evidence and acknowledging its limitations are important steps.

The peptide research field continues to evolve, with increasing interest from independent researchers potentially leading to broader scientific validation. Until human clinical trials provide definitive answers, BPC-157 remains a fascinating but incompletely understood compound with promising preclinical support.

---

References

1. Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632.

2. Sikiric P, Seiwerth S, Rucman R, et al. "Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications." Current Neuropharmacology. 2016;14(8):857-865.

3. Sikiric P, Seiwerth S, Rucman R, et al. "Pentadecapeptide BPC 157: A Review." Journal of Physiology Paris. 1999;93(1-6):481-488.

4. Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157-NO-system relation." Current Pharmaceutical Design. 2014;20(7):1126-1135.

5. Sikiric P, et al. "BPC 157 and NO system." Current Pharmaceutical Design. 2014;20(7):1126-1135.

6. Seiwerth S, et al. "BPC 157 and blood vessels." Current Pharmaceutical Design. 2014;20(7):1121-1125.

7. Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011;110(3):774-780.

8. Sikiric P, et al. "Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics." Neuropsychopharmacology. 1999;21(3):399-410.

9. Seiwerth S, et al. "BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Growth Hormone & IGF Research. 2013;23(1):47.

10. Sikiric P, et al. "Cytoprotection and pentadecapeptide BPC 157." World Journal of Gastroenterology. 2018;24(40):4585-4592.

11. Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design. 2013;19(1):76-83.

12. Sever M, et al. "Pentadecapeptide BPC 157 and the intestine-the barrier." Journal of Physiology Paris. 2001;95(1-6):365-370.

13. Hrelec M, et al. "Therapy of the short bowel syndrome–BPC 157 and esophageal, gastric, small and large intestine anastomosis." Journal of Physiology Paris. 2001;95(1-6):407-412.

14. Staresinic M, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." Journal of Orthopaedic Research. 2003;21(6):976-983.

15. Cerovecki T, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." Journal of Orthopaedic Research. 2010;28(9):1155-1161.

16. Pevec D, et al. "Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application." Medical Science Monitor. 2010;16(3):BR81-88.

17. Mihovil I, et al. "Pentadecapeptide BPC 157 attenuates systemic corticosteroid-impaired muscle healing." Journal of Musculoskeletal and Neuronal Interactions. 2009;9(4):270-279.

18. Sikiric P, et al. "The antidepressant effect of an antiulcer pentadecapeptide BPC 157 in Porsolt's test and chronic unpredictable stress in rats." Journal of Physiology Paris. 2000;94(2):99-104.

19. Gjurasin M, et al. "Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury." Regulatory Peptides. 2010;160(1-3):33-41.

20. Sikiric P, et al. "The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine, and 96% ethanol in rats." Journal of Physiology Paris. 1993;87(5):313-327.

21. Sikiric P, et al. "Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing." Current Pharmaceutical Design. 2018;24(18):1990-2001.

22. Sikiric P, et al. "Pentadecapeptide BPC 157 and its effects on a NSAID toxicity model: diclofenac-induced gastrointestinal, liver, and encephalopathy lesions." Life Sciences. 2003;73(6):757-770.

---

Disclaimer

This article is for informational and educational purposes only. BPC-157 is a research compound and is not approved by the FDA or any regulatory agency for human use. The information presented here is based on preclinical research, primarily animal studies, and should not be construed as medical advice.

Important considerations:

• BPC-157 is sold for research purposes only and is not intended for human consumption
• No human clinical trials have established safety or efficacy
• Quality and purity of research peptides vary significantly between suppliers
• BPC-157 is intended for laboratory research only and is not for human or veterinary use
• This content does not constitute medical advice, diagnosis, or treatment recommendations

For research use only. Not for human or veterinary use.

---

Keywords: BPC-157, Body Protection Compound, pentadecapeptide, gastric peptide, tissue repair research, tendon repair models, gastrointestinal research, Sikiric, Zagreb research, growth factors, VEGF, angiogenesis, FAK-paxillin, nitric oxide, peptide research

---

Frequently Asked Questions — BPC-157

The following questions address the most common research, regulatory, and product queries about BPC-157. All information is provided for educational and research reference purposes only. BPC-157 is not approved for human use.